DFFN Stock Price, Diffusion Pharmaceuticals . Quote, Chart

DFFN Stock Price

View Fullscreen

DFFN RSI Chart

DFFN Valuation

Market Cap

28.6M

Price/Earnings (Trailing)

-14.86

Price/Sales (Trailing)

3.69

EV/EBITDA

-0.99

Price/Free Cashflow

-6.58

DFFN Price/Sales (Trailing)

DFFN Profitability

Operating Margin

100.00%

EBT Margin

-295.82%

Return on Equity

-36.12%

Return on Assets

-24.1%

Free Cashflow Yield

-15.2%

DFFN Fundamentals

DFFN Revenue

Revenue (TTM)

7.8M

DFFN Earnings

Earnings (TTM)

-1.9M

Earnings Growth (Yr)

38.56%

Earnings Growth (Qtr)

-144.36%

Breaking Down DFFN Revenue

Last 7 days

11.9%

Last 30 days

20.1%

Last 90 days

-14.5%

Trailing 12 Months

-51.6%

How does DFFN drawdown profile look like?

DFFN Financial Health

Current Ratio

3.51

Debt/Equity

0.1

Debt/Cashflow

-7.1

DFFN Investor Care

Shares Dilution (1Y)

304.59%

Diluted EPS (TTM)

-9.6B

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	7.8M	0	0	0
2023	0	0	0	7.1M
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	2.9M	0
2014	1.5M	2.0M	2.4M	0
2013	1.6M	1.5M	1.3M	1.1M
2012	3.7M	3.6M	2.8M	1.8M
2011	0	2.2M	2.8M	3.3M
2010	0	0	0	1.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Diffusion Pharmaceuticals Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 30, 2023	lanchoney diana m	back to issuer	-	-	-85.00	-
Jun 30, 2023	lanchoney diana m	acquired	-	-	232	-
May 31, 2023	hollingsworth jane h	back to issuer	-	-	-68.00	-
May 31, 2023	hollingsworth jane h	acquired	-	-	183	-
Mar 31, 2023	lanchoney diana m	back to issuer	-	-	-85.00	-
Mar 31, 2023	lanchoney diana m	acquired	-	-	232	-
Feb 28, 2023	hollingsworth jane h	back to issuer	-	-	-68.00	-
Feb 28, 2023	hollingsworth jane h	acquired	-	-	183	-
Jan 31, 2023	cobuzzi robert joseph jr.	back to issuer	-	-	-121	president & ceo
Jan 31, 2023	cobuzzi robert joseph jr.	acquired	-	-	327	president & ceo

Which funds bought or sold DFFN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Jul 27, 2023	TimeScale Financial, Inc.	unchanged	-	-7.00	30.00	-%
Nov 01, 2022	Strategic Asset Management, LLC	unchanged	-	-	-	-%
Aug 15, 2022	Frontier Wealth Management LLC	sold off	-100	-7,000	-	-%
Dec 08, 2021	Homrich & Berg	unchanged	-	-2,000	5,000	-%
Jul 28, 2021	Hoover Financial Advisors, Inc.	new	-	3,000	3,000	-%

Are Funds Buying or Selling DFFN?

Are funds buying DFFN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DFFN

No. of Funds

Unveiling Diffusion Pharmaceuticals Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 11, 2024	ra capital management, l.p.	9.99%	825,373	SC 13G
Mar 06, 2024	ai eipp holdings llc	0.74%	42,556	SC 13G/A
Feb 28, 2024	boger joshua s	17.1%	1,057,268	SC 13D/A
Feb 14, 2024	ai eipp holdings llc	7.49%	428,203	SC 13G/A
Feb 09, 2024	boger joshua s	9.9%	561,309	SC 13D
Aug 28, 2023	alam john j	26.2%	1,484,078	SC 13D
Aug 28, 2023	zavrl frank	6.4%	365,621	SC 13D
Aug 28, 2023	ai eipp holdings llc	9.99%	568,811	SC 13G
Feb 14, 2020	anson funds management lp	1.6%	640,270	SC 13G/A
Feb 14, 2020	armistice capital, llc	4.99%	1,755,156	SC 13G/A

Recent SEC filings of Diffusion Pharmaceuticals Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 10, 2024	S-1	Initial Public Offering
Apr 29, 2024	DEF 14A	DEF 14A
Apr 23, 2024	8-K	Current Report
Apr 11, 2024	SC 13G	Major Ownership Report
Apr 05, 2024	8-K	Current Report
Apr 04, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 28, 2024	8-K	Current Report

Diffusion Pharmaceuticals Inc. News

Latest updates

Diffusion Pharmaceuticals Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-5.8%	2,347,250	2,490,578	1,526,482	1,407,868	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-1.7%	4,942,188	5,029,405	4,201,611	2,834,187	938,823	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	1,133,109	2,410,124	2,957,691	-1,071,093	-	-	-	-	-	-	-	-	-	-	-	-	1,290,371	1,068,452	1,200,728	1,419,087
R&D Expenses	-30.7%	2,814,258	4,060,794	1,791,487	1,308,589	-1,573,920	-	-	-	-	-	-	-	-	-	-	-	-	1,743,494	1,518,381	1,699,845	1,365,449
EBITDA Margin	8.1%	-2.96	-3.22	-7.94	-7.94	-7.94	-7.83	-8.46	-8.45	-8.44	-8.64	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	421,947	-	-	-	-	-	-	-	-	-	-	-	-	-225,960	-108,904	-150,352	45,136
Earnings Before Taxes	-	-	-	-	-	-4,075,964	-	-	-	-	-	-	-	-	-	-	-	-	-3,030,052	-2,604,302	-2,898,161	-5,525,802
EBT Margin	8.1%	-2.96	-3.22	-7.94	-7.94	-7.94	-7.84	-8.48	-8.48	-8.48	-8.68	-	-	-	-	-	-	-	-	-	-	-
Net Income	-144.4%	-2,514,335	-1,028,956	2,150,362	-4,092,384	1,134,659	-	-	-	-	-	-	-	-	-	-	-	-	-2,804,092	-2,495,398	-2,747,809	-5,570,938
Net Income Margin	49.5%	-0.25	-0.49	-0.46	-2.77	-2.92	-4.52	-8.42	-8.28	-8.32	-8.53	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	43.8%	-1,432,893	-2,547,673	2,693,546	-4,977,339	-701,749	6,847,559	-4,016,413	-4,739,032	-3,034,706	-2,981,747	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-19.8%	8.00	10.00	12.00	3.00	4.00	4.00	26.00	29.00	34.00	38.00	41.00	53.00	56.00	28.00	32.00	36.00	21.00	24.00	16.00	19.00	16.00
Current Assets	-20.1%	8.00	10.00	12.00	-	18.00	4.00	26.00	29.00	34.00	38.00	41.00	44.00	47.00	19.00	23.00	27.00	12.00	15.00	7.00	9.00	6.00
Cash Equivalents	-18.3%	6.00	8.00	10.00	15.00	15.00	4.00	5.00	6.00	10.00	7.00	40.00	43.00	47.00	19.00	22.00	26.00	11.00	14.00	6.00	8.00	5.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	2.5%	3.00	3.00	2.00	1.00	2.00	13.00	-	-	-	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	3.00
Current Liabilities	-	-	-	-	-	-	-	2.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	3.00	2.00	1.00	2.00	1.00	1.00	1.00
Shareholder's Equity	-27.7%	5.00	7.00	10.00	14.00	16.00	20.00	24.00	27.00	31.00	35.00	38.00	50.00	54.00	25.00	29.00	33.00	18.00	20.00	14.00	16.00	13.00
Retained Earnings	-4.7%	-56.96	-54.40	-52.08	-54.23	-52.80	-52.27	-141	-138	-134	-130	-126	-114	-110	-105	-101	-97.41	-94.28	-91.72	-87.97	-85.17	-82.67
Additional Paid-In Capital	0.8%	62.00	62.00	62.00	166	166	19.00	166	165	165	165	165	164	164	131	131	130	112	112	101	101	96.00
Shares Outstanding	8.7%	6.00	6.00	6.00	2.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-	-
Float	-100.0%	-	7.00	-	-	-	-	-	14.00	-	-	-	74.00	-	-	-	62.00	-	-	-	13.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	43.9%	-1,423	-2,538	2,703	-2,646	-4,968	-692	6,857	-4,007	-4,729	-3,025	-2,972	-3,327	-5,176	-3,394	-3,510	-3,143	-3,504	-2,438	-2,152	-2,610	-2,657
Share Based Compensation	32.3%	218	165	61.00	61.00	121	81.00	-303	278	278	254	164	297	181	152	279	113	191	130	145	149	91.00
Cashflow From Investing	-	-	-	-	3,000	9,500	7,000	3,380	101	-22,716	4.00	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	100.0%	-	-93.37	11,242	-	-	-	-5.00	-	5.00	-	-	-	33,296	-	-141	17,877	155	10,476	-80.21	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DFFN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Grant revenue	$ 2,347,250	$ 1,407,868
Operating expenses:
Research and development	2,814,258	1,833,274
General and administrative	2,127,930	1,000,913
Total operating expenses	4,942,188	2,834,187
Loss from operations	(2,594,938)	(1,426,319)
Other income (expense):
Other income (expense)	(30)	856,579
Interest income	80,633	35,404
Total other income, net	80,603	891,983
Net loss	$ (2,514,335)	$ (534,336)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.41)	$ (1.03)
Weighted average shares outstanding, basic and diluted (in shares)	6,170,501	518,140

DFFN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,369,172	$ 7,792,846
Deferred offering costs	247,671	0
Prepaid expenses	1,348,679	1,256,501
Grant receivable	0	915,404
Total current assets	7,965,522	9,964,751
Other assets	31,926	7,770
Total assets	7,997,448	9,972,521
Current liabilities:
Accounts payable	679,739	662,471
Deferred grant revenue	572,475	0
Accrued expenses and other current liabilities	1,408,856	1,933,276
Total liabilities	2,661,070	2,595,747
Commitments and Contingencies
Stockholders’ Equity:
Series A preferred stock $0.001 par value; 30,000,000 authorized at March 31, 2024 and December 31, 2023, 0 shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value: 1,000,000,000 shares authorized: 6,170,479 and 5,674,520 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	6,170	5,674
Additional paid-in capital	62,285,332	61,811,889
Accumulated deficit	(56,955,124)	(54,440,789)
Total stockholders' equity	5,336,378	7,376,774
Total liabilities and stockholders' equity	$ 7,997,448	$ 9,972,521

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. Frequently Asked Questions

What is the ticker symbol for Diffusion Pharmaceuticals Inc.? What does DFFN stand for in stocks?

DFFN is the stock ticker symbol of Diffusion Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Diffusion Pharmaceuticals Inc. (DFFN)?

As of Tue Apr 30 2024, market cap of Diffusion Pharmaceuticals Inc. is 28.64 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DFFN stock?

You can check DFFN's fair value in chart for subscribers.

What is the fair value of DFFN stock?

You can check DFFN's fair value in chart for subscribers. The fair value of Diffusion Pharmaceuticals Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Diffusion Pharmaceuticals Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DFFN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Diffusion Pharmaceuticals Inc. a good stock to buy?

The fair value guage provides a quick view whether DFFN is over valued or under valued. Whether Diffusion Pharmaceuticals Inc. is cheap or expensive depends on the assumptions which impact Diffusion Pharmaceuticals Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DFFN.

What is Diffusion Pharmaceuticals Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, DFFN's PE ratio (Price to Earnings) is -14.86 and Price to Sales (PS) ratio is 3.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DFFN PE ratio will change depending on the future growth rate expectations of investors.